Opthea Limited
Opthea Limited (OPT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · OPT · as of Jun 9, 2026
Key Statistics
Explore Opthea Limited Data
opt stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 62.5%
The OPT analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $2.00, representing -41.35% downside from the current price of $3.41.
Competitors & Peers
opt competitorsOPT
ABCM
ALPN
CBAY
ISEE
MORStock Performance
Full HistoryAbout Opthea Limited
Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its re…
what is opthea limited · opt stock overview · opthea limited company profile · who is opthea limited ceo · opt NASDAQ · opthea limited headquarters · opthea limited business segments
About Stock Overview & Key Data
Opthea Limited (OPT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 16, 2020. As of the latest trading session, OPT stock price is $3.41, with a market capitalization of $4.2B. The stock has returned +3.65% over the past 12 months and -7.59% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Opthea Limited stock is Buy, with an average 12-month price target of $2.00. In fiscal year 2025, Opthea Limited reported revenue of $25000.00 and net income of -$163.8M. For detailed data — including Opthea Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Opthea Limited (OPT) stock price is $3.41. The stock is traded on NASDAQ under the ticker symbol OPT. The 52-week range is $1.79 – $6.30.